Back to database

FOXO4-DRI

Also known as: Proxofim, Senolytic Peptide

Longevity / Anti-AgingPreclinicalSubcutaneousIntravenous

A senolytic peptide that selectively destroys senescent (zombie) cells by disrupting the FOXO4-p53 interaction that keeps them alive. The first peptide-based senolytic.

Molecular Weight

~4800 Da

Half-Life

~24-48 hours (D-amino acid stability)

Sequence

D-retro-inverso modified FOXO4 peptide

Mechanism of Action

Competes with endogenous FOXO4 for p53 binding. In senescent cells that depend on FOXO4-p53 interaction for survival, this releases p53 to the mitochondria to trigger apoptosis. Normal cells are unaffected.

Dosing Protocol

Research protocols: 5 mg/kg IV every 3 days for 3 doses in mouse studies. Human dosing not established.

Open peptide calculator
Reconstitution

Research-grade: lyophilized, reconstitute in sterile water.

Storage

Lyophilized: -80°C preferred, -20°C acceptable. Very expensive compound.

Side Effects
  • ●Limited human data
  • ●Theoretical risk of affecting non-senescent cells at high doses
Key Research Findings
  • ●Restored fitness, fur density, and renal function in aged mice (Cell 2017)
  • ●Selectively killed senescent cells while sparing healthy cells
  • ●First demonstration of peptide-based senolytic approach

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.